← All companies

INBX

Inhibrx Biosciences, Inc.

INBX Nasdaq Biological Products, (No Diagnostic Substances) EDGAR ↗

$82.72

-2.01 -2.37%

Key statistics

from XBRL data in SEC filings

Market cap

$1.21B

Revenue (TTM)

$1.30M

Net income (TTM)

-$130M

EPS (TTM)

$-8.39

P/E ratio

—

Dividend yield

—

Free cash flow

-$130M

Cash

$162M

Total assets

$184M

Gross margin

—

52-week range

$20.55 – $155.29

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity; Regulation FD disclosure Jul 16, 2026 8-K Regulation FD disclosure; Other events Jun 15, 2026 8-K Shareholder vote results Jun 3, 2026 8-K Results of operations (earnings release) May 14, 2026 10-Q Quarter ended 2026-03-31 May 14, 2026 8-K Regulation FD disclosure; Other events May 11, 2026 8-K Regulation FD disclosure; Other events Apr 21, 2026 8-K Results of operations (earnings release) Mar 19, 2026 10-K Fiscal year ended 2025-12-31 Mar 19, 2026 8-K Regulation FD disclosure Feb 23, 2026 8-K Regulation FD disclosure; Other events Dec 16, 2025 8-K Results of operations (earnings release) Nov 14, 2025 10-Q Quarter ended 2025-09-30 Nov 14, 2025 8-K Regulation FD disclosure; Other events Oct 23, 2025 8-K Results of operations (earnings release) Aug 13, 2025 10-Q Quarter ended 2025-06-30 Aug 13, 2025 8-K Shareholder vote results May 28, 2025 8-K Results of operations (earnings release) May 14, 2025 10-Q Quarter ended 2025-03-31 May 14, 2025 8-K Director or officer change Apr 1, 2025 8-K Results of operations (earnings release) Mar 17, 2025 10-K Fiscal year ended 2024-12-31 Mar 17, 2025 8-K Regulation FD disclosure; Other events Jan 21, 2025 8-K Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity; Regulation FD disclosure Jan 13, 2025 8-K Results of operations (earnings release) Nov 14, 2024 10-Q Quarter ended 2024-09-30 Nov 14, 2024 8-K Other events Nov 4, 2024 8-K Results of operations (earnings release); Regulation FD disclosure Aug 13, 2024 10-Q Quarter ended 2024-06-30 Aug 13, 2024 8-K Regulation FD disclosure Jun 17, 2024 8-K Entered a material agreement; Unregistered sale of equity; Modified rights of security holders; Change in control; Director or officer change; Amended charter or bylaws; Other events May 30, 2024 8-K Regulation FD disclosure May 24, 2024

Other filings

SCHEDULE 13G Aug 3, 2026 4 FORM 4 Jun 4, 2026 4 FORM 4 Jun 4, 2026 4 FORM 4 Jun 4, 2026 4 FORM 4 Jun 4, 2026 SCHEDULE 13G/A May 15, 2026 SCHEDULE 13G/A May 15, 2026 4 FORM 4 Apr 27, 2026